Crescent Capital Partners
Nigel Rigby is an accomplished business leader with extensive experience across various roles in the corporate sector. Currently serving as Investor and Director at Blue Frog Breakfast since January 2020, Executive Chairman at Crescent Capital Partners since November 2019, and Founder of Karaka Capital Ltd since September 2018, Nigel has demonstrated a strong entrepreneurial spirit. Previously, as CEO and Director at Metro Performance Glass from September 2012 to April 2018, and in multiple executive roles at James Hardie Building Products from December 2003 to July 2012, Nigel has honed leadership skills in major markets, including the US and emerging markets. Nigel is also pursuing a General Management Program at Harvard University, which adds to a robust professional profile.
This person is not in any teams
This person is not in any offices
Crescent Capital Partners
Crescent Capital Partners (Crescent) is a Sydney-based private equity firm investing in middle-market companies located in Australia and New Zealand with enterprise values between A$100 million and A$500 million. Crescent was formed in 2000 and has established itself as one of Australasia’s leading middle market private equity firms with its last three funds ranked as top quartile global funds (measured in either USD or AUD), as measured by Cambridge Associates. Crescent’s investment focus is on high-growth companies and sectors, or in industries that are undergoing structural change or that lend themselves to consolidation. Crescent’s role is to accelerate and support the senior management teams of these businesses in reaching their aspirational targets and goals. Crescent has a differentiated investment process that combines thematic and proprietary deal sourcing, with a disciplined and analytical approach to investing and a proactive approach to driving value at portfolio companies. Crescent has particular experience and skills in financial services, healthcare, branded and industrial businesses. In particular, Crescent has been the most active private equity manager in healthcare transactions in Australia measured by number of investments made in the past 10 years. Crescent has had a strong track record in delivering superior returns to investors through successful exits. Crescent is now investing our $1 billion Crescent VII (2023 vintage).